Enterome vs Gilboa Therapeutics
Enterome vs Gilboa Therapeutics, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Enterome is on 60/100 and Gilboa Therapeutics on 43/100.
Where each one leads
Enterome
- our overall score: 60/100 against 43/100
- domain rating: 46/100 against 4/100
- headcount: 33 against 2
- LinkedIn following: 16,846 against 956
Gilboa Therapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Enterome | Gilboa Therapeutics |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. | Preclinical biopharma developing next-gen cancer immunotherapies using proprietary SolidT technology. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biopharmaceuticals, Immunotherapy, Cancer Treatment, Biotechnology |
| Sells toBusiness model | B2B | B2G |
| Offering | Software | hardware | services | marketplace | platform | Hardware |
| Founded | 2012 | 2017 |
| Headquarters | Paris, France | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Enterome | Gilboa Therapeutics |
|---|---|---|
| Employees | 33 | 2 |
| Headcount growthLast 12 months | Not published | -49.5% |
| Total funding | $124M | Not published |
| Latest round | Later Stage VC | Not published |
| LinkedIn followers | 16,846 | 956 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Enterome | Gilboa Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 43/100 |
| Traction | 55/100 | 11/100 |
| Team | 70/100 | Not published |
| Search visibility | 34/100 | 54/100 |
| Quality | 68/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | F (22/100) |
| Domain ratingLink authority, 0-100 | 46/100 | 4/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Enterome | Gilboa Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | WordPress | Not detected |
| Frameworks | Bootstrap | Not detected |
| Analytics | Google Analytics 4, Segment | Not detected |
Enterome vs Gilboa Therapeutics: common questions
Which is better, Enterome or Gilboa Therapeutics?
On our 0-100 score Enterome rates higher (60/100 against 43/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Enterome and Gilboa Therapeutics compare on the numbers?
Enterome leads on our overall score (60/100 against 43/100), domain rating (46/100 against 4/100), headcount (33 against 2), LinkedIn following (16,846 against 956).
Read the full Enterome review and pricing or the Gilboa Therapeutics review and pricing. You can also browse other Enterome alternatives we track.